Mole Mapping: Managing High Risk Patients through Imaging - - PowerPoint PPT Presentation

mole mapping managing high risk patients through imaging
SMART_READER_LITE
LIVE PREVIEW

Mole Mapping: Managing High Risk Patients through Imaging - - PowerPoint PPT Presentation

Mole Mapping: Managing High Risk Patients through Imaging Disclosures Chief Medical Officer for MoleSafe USA, LLC Mole Mapping: Managing High Risk Patients through Imaging This session will focus on utilizing imaging


slide-1
SLIDE 1

Mole‐Mapping: Managing High‐Risk Patients through Imaging

slide-2
SLIDE 2

Disclosures

  • Chief Medical Officer for MoleSafe USA, LLC
slide-3
SLIDE 3

Mole‐Mapping: Managing High‐Risk Patients through Imaging

  • This session will focus on

utilizing imaging technology for the management of patients at “high‐risk” for melanoma

slide-4
SLIDE 4

ABCD’s of Melanoma

A – Asymmetry B – Border Irregularity C – Color Variegation D – Diameter great than 6 mm

slide-5
SLIDE 5

And E

E – Evolving

‐ Size ‐ Shape ‐ Symptoms ‐ Surface Bleeding ‐ Shades of Color

Abbasi,N.R.et al. Early Diagnosis of Cutaneous Melanoma.Revisiting The ABCD Criteria .JAMA. 2004;292:2771‐2776

slide-6
SLIDE 6

Defining a “High‐Risk” Patient

  • North America Definition
  • Personal History of Melanoma
  • Family History of Melanoma
  • Dysplastic Nevi
  • Many Nevi
  • Fair skin, inability to tan

Watts CG, Dieng M, Morton RL, et al. Clinical practice guidelines for identification, screening and follow‐up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology. 2015: 33‐47

slide-7
SLIDE 7

Melanoma Statistics

  • Increase in incidents rates
  • It is estimated that the number of new melanoma cases diagnosed in 2019

will increase 7.7%

  • Most new melanomas are de novo
  • How can we spot them?

American Cancer Society – Cancer Facts & Figures 2019 A meta‐analysis of nevus‐associated melanoma: Prevalence and practical implications Pampena, Riccardo et al. Journal of the American Academy of Dermatology, Volume 77, Issue 5, 938 ‐ 945.e4

slide-8
SLIDE 8
slide-9
SLIDE 9

A recent study published in the JAAD shows that there is general agreement among Pigmented Lesion Experts recommending Total Body Photography and Dermoscopic Imaging for “high‐risk” patients.

Recommendation #1: Total body photography is recommended for patients with familial atypical multiple mole melanoma syndrome (FAMMM Syndrome, aka dysplastic nevus syndrome) Strongly Agree: 91% Agree: 0% Neither Agree nor Disagree: 9% Disagree: 0% Strongly Disagree: 0% Recommendation #1: Serial digital dermoscopic imaging is recommended for montioring "ugly duckling" nevi with equivocal dermoscopic features Strongly Agree: 55% Agree: 27% Neither Agree nor Disagree: 0% Disagree: 0% Strongly Disagree: 18% Recommendation #2: Total body photography is recommended in adults with > than 50 nevi that have one or more

  • f the following: (1) a personal history of

multiple cutaneous melanomas; (2) a personal history of an amelanotic melanoma; multiple pink nevi, multiple clinically atypical nevi, and/or; (3) a genetic syndrome that predisposes to the development of cutaneous melanoma. Strongly Agree: 64% Agree: 36% Neither Agree no Disagree: 0% Disagree: 0% Strongly Disagree: 0% Recommendation #2: Serial digital dermoscopic imaging is recommended in patiets with a large or growing lentigo‐ like lesion that lack diagnostic dermoscopic features with a plan to re‐ evaluate at a three to six‐month interval Strongly Agree: 27% Agree: 55% Neither Agree no Disagree: 18% Disagree: 9% Strongly Disagree: 0% Total Body Photography Serial Digital Dermoscopic Imaging

Waldman RA, Grant‐Kels JM, Curiel CN, Curtis J, Rodriguez SG, Hu S, Kerr P, Marghoob A, Markowitz O, Pellacani G, Rabinovitz H, Rao B, Scope A, Stein JA, Swetter SM, Consensus Recommendations for the Use of Non‐Invasive Melanoma Detection Techniques Based on Results of an International DELPHI Process, Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.09.046.

slide-10
SLIDE 10

A recent study published in the JAAD shows that there is general agreement among Pigmented Lesion Experts recommending Total Body Photography and Dermoscopic Imaging for “high‐risk” patients.

Waldman RA, Grant‐Kels JM, Curiel CN, Curtis J, Rodriguez SG, Hu S, Kerr P, Marghoob A, Markowitz O, Pellacani G, Rabinovitz H, Rao B, Scope A, Stein JA, Swetter SM, Consensus Recommendations for the Use of Non‐Invasive Melanoma Detection Techniques Based on Results of an International DELPHI Process, Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.09.046.

slide-11
SLIDE 11

What is Mole‐ Mapping?

  • Combining multiple imaging techniques and

clinical follow‐up

  • Total Body Photography
  • Clinical Imaging
  • Dermoscopic Imaging

1 + 1 = 3

slide-12
SLIDE 12

Total Body Photography (TBP)

slide-13
SLIDE 13

TBP – Photographic Medical Record

Creating a benchmark, similar to an EKG or x‐ray

slide-14
SLIDE 14

Incidence of New and Changed Nevi and Melanomas Detected Using Baseline Images and Dermoscopy in Patients at High Risk for Melanoma

Jeremy P. Banky, MBBS; John W. Kelly, MDBS; Arch Dermatol. 2005;141:998-1006.

  • The use of baseline photography and dermoscopy was associated

with low biopsy rates and early detection of melanomas. Only 3 nevi were biopsied for every melanoma.

  • This compares to benign‐malignant ratios of 12:1 for dermatologists

and 30:1 for general physicians.

slide-15
SLIDE 15

TBP – Identifying New Lesions

slide-16
SLIDE 16

TBP – Identifying Changing Lesions

slide-17
SLIDE 17

Underlying Rationale of using TBP

‐ Stable lesions are biologically indolent (senescent) ‐ New/Changing lesions are biologically relevant & may represent:

‐ Melanoma ‐ Melanoma Precursor

Courtesy of Dr. Marghoob & Dr. Rabinovitz

slide-18
SLIDE 18

< 1‐3% new or changed lesions will be melanoma (clinical)

Study Year # pts. # lesions Nevi/ patient # changed # melanoma %MM/ changed Schiffner 2003 145 272 1.9 95 0.0 Bauer 2005 196 2015 10.3 128 2 1.6 Robinson 2004 100 3482 34.8 193 4 2.1 Banky 2005 309 573 18 3.1 Kittler 2000 202 1862 9.2 75 8 10.7 Menzies 2001 245 318 1.3 61 7 11.5 Hasenssle 2004 212 2939 13.9 112 15 13.4 Altamura 2008 1859 2602 1.4 487 81 16.6

Courtesy of Dr. Marghoob & Dr. Rabinovitz

TS1

slide-19
SLIDE 19

Slide 18 TS1

Taylor Sheridan, 10/11/2019

slide-20
SLIDE 20

Patients who benefit from Total Body Photography

  • Personal/Family History of melanoma
  • Atypical/Dysplastic Nevi Syndrome
  • Multiple Nevi of different size, shape, and color
  • Patient’s with high anxiety of developing melanoma
slide-21
SLIDE 21

Clinical/Dermoscopic Imaging

slide-22
SLIDE 22

How good are skin cancer specialists at diagnosing melanoma based on visual examination alone?

  • Sensitivity = 70%
  • Specificity = 75%
  • NNT (benign: malignant ratio) = 12-15
  • Bafounta. Arch Dermatol 2001;137:1343
  • Marks. JAAD;1997;36:599
  • Hansen. JAAD 2009;61:599
  • Vestergaard. BJD 2008;159:669

Carli , BJD;2004;150:687

Courtesy of Dr. Marghoob & Dr. Rabinovitz

slide-23
SLIDE 23

Diagnostic accuracy of melanoma may be improved with dermoscopy Pehamberger et al. 1993: diagnostic accuracy of 46‐54% (clinical) increasing to 62‐91% (dermoscopy)

slide-24
SLIDE 24

How good are skin cancer specialists at diagnosing melanoma with aid of dermoscopy?

  • Sensitivity = 90%
  • Specificity = 86%
  • NNT (benign:malignant ratio) = 4-7
  • Vestergaard. BJD 2008;159:669

Bafounta, Arch Dermatol 2001;137:1343

  • Hansen. JAAD 2009;61:599

Carli , BJD;2004;150:687

Courtesy of Dr. Marghoob & Dr. Rabinovitz

slide-25
SLIDE 25

Spectrum of Melanocytic Lesions

Nevi Malignant Melanoma

slide-26
SLIDE 26

Clinical Exam

There are only a few clinical features which separate melanoma from nevi.

Nevi Malignant Melanoma

Lesions in the overlapping area often require a biopsy for diagnosis. Clinically Uncertain Lesions

slide-27
SLIDE 27

Dermoscopic Exam

With dermoscopy there are dermoscopic features that correlate to benign or malignant patterns, thereby improving accuracy over clinical visual inspection

Nevi Malignant Melanoma Benign Patterns Malignant Patterns Intrinsic Limitation of Dermoscopy: Uncertain Patterns

slide-28
SLIDE 28

Sometimes a dermatoscope isn’t enough

  • Powerful tool to aid the diagnosis of early

melanomas

  • High‐risk patients need more than a “point in

time” evaluation

slide-29
SLIDE 29

Sometimes a dermatoscope isn’t enough

  • How can you spot change

without reference images?

slide-30
SLIDE 30

Short Term Surveillance

Image a suspicious melanocytic lesion that does not satisfy the classic dermoscopic criteria for the diagnosis of melanoma. The lesion is then re‐imaged at 3 month intervals. If a change is noted, the lesion is biopsied. It is believed that if a lesion is malignant, there will be a change within this time period without a significant risk to the patient.

slide-31
SLIDE 31

The Value of Serial Digital Dermoscopic Imaging (SDDI)

slide-32
SLIDE 32

Why use Mole Mapping?

  • For Providers
  • Increased Sensitivity & Specificity
  • Reduced Benign‐to‐Malignant Ratio
  • Time Restrictions
  • For Patients
  • Earlier Diagnosis
  • No more “is that all?”
  • Reduce Patient Anxiety
slide-33
SLIDE 33

How to incorporate Mole Mapping into your Practice

There are many options:

  • 1. The use of Electronic Medical Records
  • 2. Outsourcing to imaging clinics
slide-34
SLIDE 34

Thank You!